Screening novel libraries, repositioning or repurposing compounds?
Senerga® Phenotypic Screening Platform provides a time-efficient and powerful in vivo method for identifying pharmaceutically relevant activity of compounds. The proprietary consists of matrices designed to cover the maximum number of biological pathways and disease scenarios while providing predictive toxicology data.
Data generated includes up to 80 combined in vivo measurements, biomarkers and histological data points, which are then analyzed using a proprietary algorithm to identify hit compounds that modulate relevant biological processes. Observations from Senerga® PS may provide greater predictability than in vitro screening methods, which lack complex biological systems often leading to unpredicted biological interactions when taken into animal or human subjects.
The Senerga® PS Platform can be run in its entirety or modified to accommodate specific objectives of each compound library. The platform can be applied to libraries with as few as 50 compounds and as many as 1500 compounds. Processed results are provided within short time frames, allowing SAR analysis, chemistry modifications and compound development as well as future data mining.
Contact us for collaborative projects including the screening of proprietary, novel libraries or for repurposing of existing or failed compounds!